• • 

    

    Mark A. Socinski, MD

    Peer

  • 

    

    Jyoti Patel, MD

    Peer

  • 

    

    Benjamin Levy, MD

    Peer

  1

  

  RestartResume

  RestartResume

  Practical Considerations on the Use of Immune Checkpoint Inhibitors & Chemoth...

• • 

    

    Mitesh J. Borad, MD

    Peer

  • 

    

    Milind Javel, MD

    Peer

  2

  

  RestartResume

  RestartResume

  Rethinking Approaches to Biliary Tract Carcinoma

• • 

    

    Alfredo L. Falcone, MD

    Peer

  • 

    

    Sebastian Stintzing, MD

    Peer

  • 

    

    Tianshu Liu, MD

    Peer

  3

  

  RestartResume

  RestartResume

  Considerações Clínicas na Sequenciação do Tratamento do CCRM

• • 

    

    Anne S. Tsao, MD

    Peer

  5

  

  RestartResume

  RestartResume

  Managing Patients With Advanced NSCLC Without a Driver Mutation in the Second...

• • 

    

    Robert Mocharnuk, MD

    Peer

  • 

    

    Joshua Bauml, MD

    Peer

  2

  

  RestartResume

  RestartResume

  Distilling Modern Medical Approaches in Advanced NSCLC: Precision, Performanc...

• • 

    

    Kenneth C. Anderson, MD

    Peer

  • 

    

    Philippe Moreau, MD

    Peer

  6

  

  RestartResume

  RestartResume

  Real-World Treatment Effectiveness Compared with Clinical Trial Efficacy in M...

Featured

• • 

    

    Scott Kopetz, MD, PhD, FACP

    Peer

  • 

    

    Alberto Sobrero, MD

    Peer

  • 

    

    Rui-Hua Xu, MD

    Peer

  17

  

  RestartResume

  RestartResume

  Improving Clinical Practice in Management of mCRC: A Focus on Tumor Sidedness

• • 

    

    Timothy A. McCarthy, MD

    Peer

  13

  

  RestartResume

  RestartResume

  Precision Oncology: Incorporating Next Generation Sequencing (NGS) in NSCLC

• • 

    

    Edward S. Kim, MD

    Peer

  3

  

  RestartResume

  RestartResume

  The Value of Multidisciplinary Teams in NSCLC Care Plans

• • 

    

    Alfredo L. Falcone, MD

    Peer

  • 

    

    Sebastian Stintzing, MD

    Peer

  • 

    

    Tianshu Liu, MD

    Peer

  6

  

  RestartResume

  RestartResume

  Clinical Considerations in Treatment Sequencing for mCRC

• • 

    

    Athanassios Argiris, MD, PhD, FACP

    Peer

  2

  

  RestartResume

  RestartResume

  Role of Immunotherapy in Head & Neck Cancer

• • 

    

    Tanguy Seiwert, MD

    Peer

  4

  

  RestartResume

  RestartResume

  Current Recommendations: HPV Tumors in Head & Neck Cancers
• 4

  

  RestartResume

  RestartResume

  Recent Breakthroughs in Head and Neck Cancer
• 3

  

  RestartResume

  RestartResume

  Management of Head & Neck Cancer

• • 

    

    Athanassios Argiris, MD, PhD, FACP

    Peer

  2

  

  RestartResume

  RestartResume

  Key Developments within Head & Neck Cancer
• 3

  

  RestartResume

  RestartResume

  Colorectal Cancer Physician Resources
• 4

  

  RestartResume

  RestartResume

  Head and Neck Physician Resources
• 10

  

  RestartResume

  RestartResume

  Interview with Makoto Tahara, MD, PhD | Japan